This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2004 Nov;1(1):2-3.

doi: 10.1038/ncponc0007.

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

Jonathan E Dowell¹, John D Minna

Affiliations

PMID: 16264773
DOI: 10.1038/ncponc0007

Review

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

Jonathan E Dowell et al. Nat Clin Pract Oncol. 2004 Nov.

. 2004 Nov;1(1):2-3.

doi: 10.1038/ncponc0007.

Authors

Jonathan E Dowell¹, John D Minna

Affiliation

¹ Dallas Veterans Affairs Medical Center, TX, USA.

PMID: 16264773
DOI: 10.1038/ncponc0007

No abstract available

PubMed Disclaimer

Similar articles

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Shih JY, Gow CH, Yang PC. Shih JY, et al. N Engl J Med. 2005 Jul 14;353(2):207-8. doi: 10.1056/NEJM200507143530217. N Engl J Med. 2005. PMID: 16014893 No abstract available.
Medicine. Why a new cancer drug works well, in some patients.
Marx J. Marx J. Science. 2004 Apr 30;304(5671):658-9. doi: 10.1126/science.304.5671.658a. Science. 2004. PMID: 15118127 No abstract available.
Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
Schwab R, Pinter F, Moldavy J, Papay J, Strausz J, Kopper L, Keri G, Pap A, Petak I, Oreskovich K, Mangel L. Schwab R, et al. J Clin Oncol. 2005 Oct 20;23(30):7736-8. doi: 10.1200/JCO.2005.02.4760. J Clin Oncol. 2005. PMID: 16234532 No abstract available.
Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.
Riedel RF, Febbo PG. Riedel RF, et al. Future Oncol. 2005 Aug;1(4):461-6. doi: 10.2217/14796694.1.4.461. Future Oncol. 2005. PMID: 16556022 Review.
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF, Reck M. Heigener DF, et al. Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Adv Ther. 2011. PMID: 21181318 Review.

See all similar articles

Cited by

PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J. Kozaki K, et al. Cancer Sci. 2006 Dec;97(12):1351-8. doi: 10.1111/j.1349-7006.2006.00343.x. Cancer Sci. 2006. PMID: 17052259 Free PMC article.
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Aleksakhina SN, Imyanitov EN. Aleksakhina SN, et al. Int J Mol Sci. 2021 Oct 10;22(20):10931. doi: 10.3390/ijms222010931. Int J Mol Sci. 2021. PMID: 34681592 Free PMC article. Review.
Translational research in oncology--10 years of progress and future prospects.
Doroshow JH, Kummar S. Doroshow JH, et al. Nat Rev Clin Oncol. 2014 Nov;11(11):649-62. doi: 10.1038/nrclinonc.2014.158. Epub 2014 Oct 7. Nat Rev Clin Oncol. 2014. PMID: 25286976 Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program